Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transpl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood cancer journal (New York) 2022-09, Vol.12 (9), p.140-140, Article 140
Hauptverfasser: Raj, Kavita, Eikema, Dirk-Jan, Sheth, Vipul, Koster, Linda, de Wreede, Liesbeth C., Blaise, Didier, Di Grazia, Carmela, Koc, Yener, Potter, Victoria, Chevallier, Patrice, Lopez- Corral, Lucia, Wu, Depei, Mielke, Stephan, Maertens, Johan, Meijer, Ellen, Huynh, Anne, Passweg, Jakob, Luft, Thomas, Pérez-Simón, Jose Antonio, Ciceri, Fabio, Piekarska, Agnieszka, Hayri Ozsan, G., Kröger, Nicolaus, Robin, Marie, Yakoub-Agha, Ibrahim
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD ( p  
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-022-00729-y